Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70365 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Emili Anderson and 5 co-authors. Institution: UNC Medical Center, Chapel Hill, North Carolina, USA. Major MEDLINE topics: Proteinuria, Sodium-Glucose Transporter 2 Inhibitors, Kidney Transplantation, Diabetes Mellitus, Type 2. Cited 3 times so far (Crossref); 29 references.
Abstract (original language)
Introduction
Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protection in chronic kidney disease, regardless of type 2 diabetes mellitus (T2DM) status. However, data evaluating SGLT2i impact on cardiorenal outcomes in kidney transplant recipients (KTRs) are limited.
Methods
This single‐center, retrospective cohort study evaluated the safety and efficacy of SGLT2i therapy in adult KTRs transplanted between January 1, 2020 and December 31, 2023. Primary outcomes were changes in urine protein‐to‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1‐, 3‐, 6‐, and 12‐months post‐initiation. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR), BMI, and hemoglobin A1c (HbA1c). Safety outcomes were cardiovascular hospitalization, acute kidney injury, urinary tract infection, and biopsy‐proven rejection within 12 months.
Results
SGLT2i therapy was initiated in 77 KTRs, 524 days post‐transplant, predominantly in males (74.3%), African Americans (62.8%), and patients with T2DM (80.7%). Baseline UPCR and UACR were 0.387 g/g and 302.2 mg/g, respectively. No significant changes in UPCR, UACR, or eGFR were observed. Renal function was preserved at 12 months, with a transient decline at 1‐month that returned to baseline by 3 months. HbA1c and BMI remained stable. Few safety events occurred.
Conclusions
In KTRs with moderate proteinuria, SGLT2i therapy was well tolerated with stable renal function over 12 months. A transient eGFR dip is consistent with patterns seen in non‐transplant populations. Absence of significant metabolic changes may reflect well‐controlled baseline parameters. Further studies are warranted to evaluate SGLT2i benefits in KTRs, especially in patients with higher grade proteinuria or early post‐transplant initiation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- UNC Medical Center, Chapel Hill, North Carolina, USA.
ORCID profiles: Emili Anderson, Stephanie Shabanowitz, Rachel Bassett Allen, Mary Chandran, Anita Yang
Cite
APA
Anderson, E., Shabanowitz, S., Jessup, K., Allen, R. B., Chandran, M., & Yang, A. (2025). Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70365
Vancouver
Anderson E, Shabanowitz S, Jessup K, Allen RB, Chandran M, Yang A. Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70365
BibTeX
@article{Anderson2025,
author = {Anderson, Emili and Shabanowitz, Stephanie and Jessup, Kinley and Allen, Rachel Bassett and Chandran, Mary and Yang, Anita},
title = {Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70365}
}
EUVIMED